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ATBACKGROUND & AIMS: There are fewvalidatedbiomarkers that
can be used to predict outcomes for patients with colorectal can-
cer. Part of the challenge is the genetic and molecular heteroge-
neity of colorectal tumors not only among patients, but alsowithin
tumors. We have explored intratumor heterogeneity at the
epigenetic level, due to its dynamic nature. We analyzed DNA
methylation proﬁles of the digestive tract surface and the central
bulk and invasive front regions of colorectal tumors. METHODS:
We determined the DNA methylation proﬁles of >450,000 CpG
sites in 3 macrodissected regions of 79 colorectal tumors and 23
associated liver metastases, obtained from 2 hospitals in Spain.
We also analyzed samples for KRAS and BRAF mutations,
499,170 single nucleotide polymorphisms, and performed
immunohistochemical analyses. RESULTS: We observed differ-
ences in DNA methylation among the 3 tumor sections; regions
of tumorhost interface differed the most from the other tumor
sections. Interestingly, tumor samples collected from areas
closer to the gastrointestinal transit most frequently shared
methylation events with metastases. When we calculated indi-
vidual coefﬁcients to quantify heterogeneity, we found that
epigenetic homogeneity was signiﬁcantly associated with short
time of relapse-free survival (log-rank P ¼ .037) and short time
of overall survival (log-rank P ¼ .026) in patients with locore-
gional colorectal cancer. CONCLUSIONS: In an analysis of 79
colorectal tumors, we found signiﬁcant heterogeneity in patterns
of DNA methylation within each tumor; the level of heteroge-
neity correlates with times of relapse-free and overall survival.Abbreviations used in this paper: CB, central bulk; CRC, colorectal
cancer; EH, epigenetic homogeneity; FFPE, formalin-ﬁxed parafﬁn-
embedded; HR, hazard ratio; IF, invasive front; MSI, microsatellite insta-
bility; SNP, single nucleotide polymorphism; TS, tract surface.
Most current article
© 2016 by the AGA Institute. Published by Elsevier Inc. This is an open
access article under the CC BY-NC-ND license (http://creativecommons.
org/licenses/by-nc-nd/4.0/).Keywords: Colorectal Cancer; Epigenetics; DNA Methylation;
Heterogeneity.
olorectal cancer (CRC) is the second most common
10016-5085
http://dx.doi.org/10.1053/j.gastro.2016.08.001Ccancer cause of death in developed countries.
Despite increased understanding of the molecularpathways underlying CRC, few prognostic biomarkers have
been established to estimate survival.2 This is partly due to
the heterogeneous nature of the disease. At the intertu-
moral level, different genetic3 and epigenetic4 alterations
could deﬁne several subtypes of colorectal primary
tumors. However, the lack of knowledge about the
molecular defects that drive metastatic disease,5 which
causes of 90% of cancer morbidity, represents a major
drawback in our ability to deﬁne accurate prognostic
markers. Interestingly, it is widely accepted that most
tumors operate through clonal sweeps and branched
evolution, produced from sequential selection of acquired
phenotypic traits,6 and it is also known that intratumoral
genetic diversity takes place.7,8 But there are important
constraints to intratumoral genetic diversity that are less
evident with epigenetic changes, which are plastic in
nature.9 For this reason, shifts in the DNA methylation
patterns have been involved in metastasis formation10 or
chemoresistance.11 We studied the extent of intratumoral
epigenetic heterogeneity in CRC and whether it has any
impact in patient prognosis.
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Clinical, Molecular, and Histopathologic
Characteristics of Colorectal Cancer Patients
This was a retrospective study of 79 CRC patients.
Formalin-ﬁxed parafﬁn-embedded (FFPE) tissue was obtained
by surgical resection in 2 different Spanish hospitals (Hospital
Germans Trias i Pujol, Catalan Institute of Oncology, Badalona
and Hospital Vall d’Hebron, Barcelona). Signed informed con-
sent was obtained from each patient. Twenty-three of the 79
primary tumors had tissue available from paired liver metas-
tases: 10 synchronous and 13 metachronous. Clinical and his-
topathologic characteristics of the patients are shown in
Table 1. Brieﬂy, 80% of patients presented local disease (stage
I, II, or III) at diagnosis, while the remainder had metastases.
Microsatellite instability (MSI) was present in 14% (11 of 79)
of tumors, all of which were from patients with local disease.
Complete clinical data necessary for survival analysis were
available in 71 of 79 patients, 11% of which had MSI (8 of 71)
and 18% of which (13 of 71) had advanced disease. Patients
who received adjuvant treatment were treated with ﬂuo-
ropyrimidines and oxaliplatin based-therapy. An additional set
of stage IV CRC tumors (n ¼ 17) was also included in the study.
Histopathologic parameters were assessed in the PathologyTable 1.Clinical and Histopathologic Characteristics of
Colorectal Cancer Cohort (n ¼ 79)
Characteristic n (%) Parameter n (%)
Sex Survival
Male 62 (78) Relapse
Female 17 (22) Yes 26 (33)
Age No 45 (57)
<60 y 16 (20) Unknown 8 (10)
>60 y 48 (61) Survival status
Unknown 15 (19) Alive 58 (73)
Stage Death 13 (17)
Locoregional disease 63 (80) Unknown 8 (10)
Advanced disease 16 (20) Histopathologic
Localization Histology subtype
Right colon 31 (39) ADC 63 (80)
Left colon 48 (60) ADC mucinous or PD 14 (18)
MSI status Unknown/NA 2 (2)
MSS 68 (86) Type of IF
MSIþ 11 (14) Expansive 39 (49)
KRAS status Inﬁltrative 36 (46)
Wild-type 56 (71) Unknown/NA 4 (5)
Mutated 23 (29) Tumor budding
BRAF status No/low 54 (69)
Wild-type 68 (86) Medium/high 20 (25)
Mutated 11 (14) Unknown/NA 5 (6)
Liver metastasis Tumor inﬂammation
Metachronous 13 (16) No/low 45 (57)
Synchronous 10 (13) Medium/high 32 (41)
No metastasis/NA 56 (71) Unknown/NA 2 (2)
Adjuvant treatment Tumor necrosis
Yes 58 (74) No/low 60 (76)
No 13 (16) Medium/high 14 (18)
Unknown 8 (10) Unknown/NA 5 (6)
ADC, adenocarcinoma; MSS, stable tumors; NA, not avail-
able; PD, poorly differentiated.Unit of Hospital Germans Trias i Pujol (Badalona) using H&E
staining and optic microscope.
Delimitation of Primary Intratumoral Regions
All 79 FFPE primary tumors underwent macrodissection
(Figure 1A). Three different tumor regions were assessed at the
Pathology Unit of Hospital Germans Trias i Pujol (Badalona),
using H&E staining and optic microscope. All cancer specimens
contained at least 80% of carcinoma cells for each intratumoral
section. Stromal and inﬂammatory cells were also counted for
each region. Three regions were deﬁned: the region nearest the
digestive tract surface (TS), the central bulk (CB), and the
invasive front (IF).
DNA Extraction and Quality Control
After deparafﬁnization by Xylene and tissue digestion by
proteinase K (Qiagen, Venlo, The Netherlands), DNA was
extracted using E.Z.N.A FFPE DNA extraction kit (Omega
Bio-Tek Inc, Norcross, GA) following the manufacturer’s
instructions. DNA was quantiﬁed by ﬂuorometric method
(Quant-iT PicoGreen dsDNA Assay; Life Technologies, Carlsbad,
CA) and checked for its suitability for FFPE restoration, as
indicated on Inﬁnium HD FFPE QC Assay (Illumina Inc., San
Diego, CA), by performing a quantitative polymerase chain
reaction with 2 ng FFPE DNA. DCq value was calculated by
subtracting the mean Cq value of the interrogated sample to the
Cq value of a standard provided by the manufacturer. All
samples resulted in DCq < 5, which is the threshold recom-
mendation for suitability of samples for FFPE restoration.
DNA Methylation Analysis
DNA bisulﬁte conversion was carried out using 300 ng DNA
randomized on a 96-well plate using EZ-96 DNA Methylation
kit (Zymo Research Corp, Irvine, CA) following the manufac-
turer’s recommendations for Inﬁnium assays. Bisulﬁte-
converted DNA was processed with the Inﬁnium FFPE
restoration process and then hybridized on Inﬁnium Human-
Methylation450 BeadChip array following the manufacturer’s
instructions for automated processing of the arrays with a
liquid handler (Illumina Inﬁnium HD Methylation Assay
Experienced User Card, Automated Protocol 15019521 v01).
We normalized raw-intensity data using manufacturer’s
method (GenomeStudio) implemented on minﬁ package (pre-
processIllumina; minﬁ, version 1.12), as this method relies on
the fact that ﬁxed amounts of the different control oligonucle-
otides have been added to the different reagents used during
array sample processing. As the amounts of each control
oligonucleotides are the same for all samples and beadchips
used, normalization method makes the necessary adjustments
so control intensities are comparable among beadchips and
samples within it. Normalized intensities were transformed
into b values by computing per marker the quotient between
methylated intensity divided by the sum of methylated and
unmethylated intensities and a offset of 100 (to avoid dividing
with small values). The obtained values were uploaded to GEO
repository under accession numbers GSE69550, GSE81359,
GSE81362, and GSE81472. After the normalization step, probes
related to X and Y chromosomes were removed, as well as
those probes with 10 bases nearer the interrogated site that
contained a single nucleotide polymorphism (SNP), as
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Methylation450, version 1.2 manifest ﬁle). In addition, CpG
sites with associated P values from channel detection >.01
were discarded for the analysis. To assert that the 3 different
tumoral types per patient were being used correctly, probes
designed within the microarray to target 65 SNPs were used to
ensure proper comparison of patient samples. Technical repli-
cates were obtained for 12 intratumoral samples.
Unsupervised heatmap representation of the 3 different
tumoral regions (TS, CB, and IF) for the whole cohort of
patients was generated using randomly selected 1% of the CpG
sites and organizing them by applying a hierarchical clustering
method on Manhattan distances aggregated by Ward’s linkage.
Similarly, per patient, hierarchical clustering of Manhattan
distances aggregated by ward’s linkage over the top 1% of CpG
sites, with the greatest differences on methylation values
among intratumoral regions were considered. The robustness
of the identiﬁed groups was determined using multiscale
bootstrap resampling (n ¼ 1000).
Coefﬁcient of Epigenetic Homogeneity
In order to estimate the level of intratumoral epigenetic
homogeneity, we calculated a coefﬁcient based on the epige-
netic changes among the 3 regions. SD mean promoters coef-
ﬁcient was used to compute the SD across the 3 intratumoral
regions (TS, CB, and IF) for each patient and each marker that
passed our ﬁltering procedures, which consisted of the
following exclusion criteria: probes outside promoters (ac-
cording to promoter regions of Ensembl genes, version
Ensembl Genes 75), probes located in sex chromosomes, probes
with detection P values >.01, and probes interrogating non-
CpG sites. The score for a patient was computed according to
the equation:
SD mean promoters ¼ 1
N
XN
i¼ 1
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
1
3 1
X3
j¼ 1

bj;i  bi
2
vuut
where N is total number of ﬁltered CpG sites interrogated in the
microarray, i is one of the ﬁltered CpG sites, j is 1 of the 3
intratumoral regions (TS, CB, and IF), and b is the methylation
value. A similar approach has been used to quantify intra-
tumoral genetic heterogeneity.12 The lowest value indicates the
highest level of homogeneity, meaning a lower heterogeneity.
Immunohistochemistry
Immunohistochemistry was performed using EnVision þ
Dual Link System-HRP, DABþ (Dako, Carpinteria, CA) according
to manufacturer’s instructions, using the PRDM16 (ab118573;
Abcam, Cambridge, MA, dilution 1:1000; epidermis as positive
control tissue) and OPCML (ab100923, Abcam, dilution 1:200;
fetal brain as external positive control) antibodies. Samples
were additionally counterstained with hematoxylin.
Mutational Analysis
KRAS and BRAF mutational status was determined through
standard Sanger sequencing using speciﬁc primers for genomic
DNA (available upon request). The mutational analysis included
codons 12 and 13 for KRAS and the V600E mutation for BRAF
for the 3 different intratumoral regions for each tumor.Single Nucleotide Polymorphism Microarray
SNP genotypes were determined using the Illumina Inﬁn-
ium OncoArray-500K. FFPE genomic material (200 ng) was
restored using Illumina Restoration Kit. Restored DNA was
treated following manufacturer’s protocol for Inﬁnium HTS
assay. Genotypes, SNPs GeneTrain scores, as well as genotyping
call scores, were extracted from GenomeStudio (V2011.1;
Genotyping module V1.9.4) using manufacturers cluster ﬁle
speciﬁc for OncoArray-500K. Obtained data were processed
under R statistical environment (version 3.1.1), ﬁltering out
unreliable genotypes (GeneTrain score 0.6; genotype call
score 0.6). Patient genotype concordance rates were
computed by counting the number of markers matching in all 3
intratumoral regions.Calculation of Z-Scores
Using the 20 normal colon samples included in our study,
mean (mi
[N]) and SD (si
[N]) per probe (i) were computed. The
z-score of each probe and intratumoral region (j) was
computed according to the following formula:
zij ¼
bi;jmðNÞi

s
ðNÞ
i  x
where a regularization parameter, x ¼ .02 was chosen after
considering the distribution of probe SDs in normal samples.
This regularization parameter was introduced in the z-score
formula to prevent very large values from occurring. Per
intratumoral region, the mean of all z-scores of probes located
on promoters were calculated and used to analyze whether an
intratumoral region showed more or less differences with
normal tissue than others.Statistical Analyses
Signiﬁcant differences in percentages distribution were
assessed using the c2 goodness-of-ﬁt test. The c2 goodness-of-
ﬁt test is applied when you have one categorical variable from a
single population. The test determines whether a distribution of
data or scores for one nominal (categorical) variable matches
theoretical expectations for that distribution. In our case, we
used the test to evaluate which percentages, calculated for all
cohorts according to which was the most divergent intratumor
region, were statistically signiﬁcant with respect to theoretical
expectations for that distribution. In order to evaluate the
impact of the level of intratumoral epigenetic homogeneity
(EH) in CRC prognosis, we performed survival analysis based
on Kaplan-Meier plots, estimating the effect of EH level in
relapse-free survival and overall survival. Epigenetic homoge-
neity level was calculated using the SD mean promoters coef-
ﬁcient described. Two groups were established (high and low
homogeneity level) using the quartile 50 (median) of SD mean
promoters coefﬁcient as threshold value. Kaplan-Meier plots
were drawn and compared with the 2-sided log-rank test. To
study the role of EH level in survival considering the effect of
other clinical, histopathologic and molecular covariables, haz-
ard ratios (HRs) and their 95% conﬁdence intervals were
estimated using multivariate Cox proportional hazards regres-
sion models, considering as independent prognostic factor
covariables with P < .05. Results were further validated by
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Figure 2. Epigenetically
divergent regions and
immunohistochemistry
validation. (A) Percentage
of patients classiﬁed ac-
cording to which is the
most DNA methylation
divergent intratumoral re-
gion when patients were
assessed individually: TS;
CB; and IF. Divergence
was calculated by SD
among intratumoral re-
gions, using supervised
clustering analysis,
comparing all CpGs in
promoter sequences. (B)
Inmunohistochemistry
staining in 2 independent
colorectal tumors to show
the correlation between
methylation levels and
protein expression of 2
candidate genes. Protein
expression (brown stain-
ing) of PRDM16 is
observed in the TS that
was found unmethylated
for the PRDM16 promoter,
whereas the invasive front
was hypermethylated and
PRDM16 expression was
not detected. For the
OPCML gene, the oppo-
site pattern is observed in
the second tumor:
expression is found in the
unmethylated IF (brown
staining), whereas loss of
staining is found in the
hypermethylated TS.
=
Figure 1. Analysis of intratumoral DNA methylation heterogeneity. (A) Example of a tumor macrodissection of FFPE tissue from
CRC patients. Different intratumoral regions were assessed using H&E staining and optic microscope and were described
as region nearest digestive TS, CB, and IF. (B) Unsupervised clustering analysis of whole CRC primary intratumoral regions
(n ¼ 237, corresponding to the 3 intratumoral regions from 79 patients) using hierarchical ward agglomeration method for the
Manhattan distances of the interrogated CpGs (a 1% randomly selected subset of CpGs from the DNA methylation microarray
is shown). Color-coded regions as blue (TS), yellow (CB), and red (IF).
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November 2016 Predicting Outcomes in Patients With CRC 967performing a bootstrap resampling procedure among 1000
new models. Kaplan-Meier plots and log-rank test were also
applied for the determination of the effect of which was most
divergent intratumoral region (IF, CB, or TS) in survival. The
associations between the categorical covariables and low or
high epigenetic homogeneity level were assessed by using the
c2 or Fisher’s exact test, as required, considering a statistical
signiﬁcant association when P < .05. Differences between
categorical variables and EH level were assessed using
Mann-Whitney U nonparametric test in cases where SD mean
promoters were applied as a continuous (quantitative) variable.
Pearson’s test was calculated to establish the correlation be-
tween continuous variables (number of differences in genotype
vs in methylation), considering r > 0.5 and P < .05 as positive
correlation.BA
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Intertumoral Epigenetic Heterogeneity Is Higher
Than Intratumoral Diversity
We analyzed the DNA methylation proﬁles of >450,000
CpG sites13 of 79 colorectal tumors (Table 1) in 3 macro-
dissected regions for each sample. These 3 intratumoral
sections corresponded to a region more exposed to the
gastrointestinal transit, the digestive TS; a region corre-
sponding to the middle of the surgical tumoral piece, the CB,
and a region close to the tumorhost interface, the IF
(Figure 1A). We observed ﬁrst in the unsupervised analysis
that each of the 3 tumor sections preferentially clustered
within each CRC patient (65.8%; 52 of 79) (multiscale
bootstrap resampling, n ¼ 1000, P < .05), thus, intertumoral
epigenetic heterogeneity was signiﬁcantly higher than
intratumoral DNA methylation diversity (c2 goodness-of-ﬁt
test: P ¼ .005) (Figure 1B). Technical replicates of a sub-
set of the experimental tissue samples (12 intratumoral
regions from 4 CRC patients) showed high reproducibility
(Pearson’s coefﬁcient r ¼ 0.98 [0.970.99]; P ¼ 2.22 
1016)] (Supplementary Figure 1). If we only require that at
least 2 of the 3 intratumoral regions cluster together, the
percentage reached 100% of cases (Figure 1B). Principal
component analysis also showed that the same intratumoral
section from different patients did not cluster together
(Supplementary Figure 2). In this regard, colorectal tumors
undergo promoter CpG island methylation of tumor=
Figure 3. Analysis of genetic vs epigenetic intratumoral heterogene
amongprimary intratumoral regions (TS,CB,and IF) inasetofCRCc
Manhattan distances of the SNPs interrogated with Illumina Inﬁnium
genotypes (GeneTrain score0.6; genotypecall score0.6). Color
lightgreen (BB¼2).Colorcoded intratumoral regionswere red (IF),ye
the most frequently genetic divergent intratumoral region in a set o
genotype discordanceswere computed by counting the number of
with the remainingones. (C) Scatter plot forCRCpatients, using then
showing genotypedifferences among intratumoral regions (Pearson
individual genotype (left) and epigenetic (middle) differences in a set
regions.Patientgenotypediscordanceswerecomputedcounting th
discordantwith the remaining ones.Methylation differenceswere co
their differencewith the third intratumoral regionwas>10%. In right,
SNPs in the studied 9 patients (2-sided t-test, P ¼ .0014).suppressor genes that can differ between patients.14,15 For
example, MSI was present in 14% (11 of 79) of tumors, and
these cases showed an enrichment in a speciﬁc DNA
methylation pattern, which has been previously named as
CpG island methylator phenotype,16 which distinguished
them from the microsatellite stable tumors (86%, 68 of 79)
(Supplementary Figure 3). Examples of hypermethylated
CpG island methylator phenotypeassociated genes in our
samples included CRABP1 and NEUROG1.17 These data
conﬁrm that there is more intertumoral than intratumoral
heterogeneity present, as described previously.18 Unsuper-
vised clustering analysis of 20 paired normal colorectal
mucosa samples showed that most of them cluster together,
not with any intratumoral section of the corresponding
patient (Supplementary Figure 4). To further prove that we
were measuring tumor-speciﬁc methylation differences and
not underlying normal tissue epigenetic variation for these
patients, we used the 20 available normal matched tissues
to calculate a probe z-score statistic, as described previ-
ously.19 None of the different intratumoral regions showed
statistically signiﬁcant differences according to this factor
(pairwise t-test P > .05) (Supplementary Figure 5).Invasive Front Is the Most Epigenetically
Divergent Region
We then proceeded to develop individualized unsuper-
vised clustering analyses for each CRC patient. This
approach showed that there was a common DNA methyl-
ation proﬁle among the 3 studied locations where 90.9%
(range, 70.5%99.4%) of the CpGs had identical methyl-
ation levels (SD of CpG sites calculated per patient within
the 3 intratumoral regions <0.1) in a given case, but 9.1%
(range, 0.6%29.5%) of methylation sites were distinct (SD
> 0.1) between the described regions among the interro-
gated 485,577 CpG dinucleotides. The most epigenetically
divergent region was the IF (c2 goodness-of-ﬁt test,
P ¼ .01), a phenomenon occurring in half of the cases
(49.4% [39 of 79]), while for the remaining cases, the most
different section was either the CB (25.3% [20 of 79]) or the
digestive TS (25.3% [20 of 79]) (Figure 2A). This observa-
tion ﬁts with the idea that the IF represents a critical
interface for molecular changes in colorectal carcinoma
that includes changes in adhesion molecules andity. (A) Unsupervised clustering analysis of genotyping differences
ases (n¼9), usinghierarchicalwardagglomerationmethod for the
OncoArray-500K. Obtained data were ﬁltered out of unreliable
codedgenotypeswere light blue (AA¼ 0),dark green (AB¼ 1) and
llow (CB) anddarkblue (TS). (B)Barplot representationofwhich is
f patients assessed individually (n ¼ 9): TS; CB; and IF. Patient
markers for which at least one intratumoral regionwas discordant
umber of differentiallymethylatedCpGsand thenumber of SNPs
’s correlation r¼0.062;P¼ .56). (D) Graphical representation of
of samples (n¼ 9), comparing for each patient the 3 intratumoral
enumberofmarkers forwhichat leastone intratumoral regionwas
nsideredwhenSDamong 2 intratumoral regionswas<0.05, and
boxplots representingmedianvaluesof differences forCpGsand
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observed any association between the most and the least
divergent regions within each patient (c2 goodness-of-ﬁt;
P ¼ .84). Overall, according to analysis of variance after
conducting pairwise comparisons across the 3 intratumoral
regions from combined probe data in all patients, we
observed 3002 CpGs (Supplementary Table 1) with statis-
tically signiﬁcant changes (false-discovery rateadjusted
P < .01, Db > .10).
For further validation of our assay, we used immuno-
histochemistry, which is one of the most accepted
approaches to studying molecular heterogeneity in a tissue.
Our DNA methylation analyses identiﬁed, among other
genomic sites, genes with differential DNA methylation
status of their promoters, which are associated with loss of
expression. We selected 2 genes with distinct DNA methyl-
ation patterns among the 3 intratumoral sections and tested
their expression by immunohistochemistry. We found that
the DNA methylation status in each region was associated
with the expected expression patterns for the PRDM16
(n ¼ 11) and OPCML (n ¼ 5) proteins: hypermethylation
was linked to diminished expression and an unmethylated
status was associated with high expression. Illustrative ex-
amples for the 2 genes are shown in Figure 2B.
From a genetic standpoint, we detected the presence of
KRAS or BRAF mutation in 29% and 14% of the studied
colorectal tumors, respectively, that were present
throughout the 3 intratumoral regions (Supplementary
Figure 6). We studied the contribution of the genetic
component in the generation of heterogeneity by interro-
gating 499,170 SNPs in the 3 intratumoral sections. The
unsupervised clustering analysis of the SNP microarray in 9
CRC patients from our studied set showed that each of the 3
tumor sections clustered within each CRC patient (100%; 9
of 9) (multiscale bootstrap resampling, n ¼ 1000; P < .05).
Thus, as it also occurred with the epigenomic assessment,
intertumoral heterogeneity was higher than intratumoral
diversity at the SNP array level (Figure 3A). Interestingly,
the most SNP-divergent intratumoral section was the IF (c2
goodness-of-ﬁt test; P ¼ .01), a phenomenon occurring in
close to half of the studied cases (44.4% [4 of 9])
(Figure 3B). This is the same region that we found most
divergent at the epigenetic level, however, the SNPs asso-
ciated with heterogeneity (Supplementary Table 2) did not
correlate with the CpG dinucleotides displaying methylation
heterogeneity (Supplementary Table 1) as shown in
Figure 3C (Pearson’s correlation r ¼ 0.062; P ¼ .56). Most
important, the number of CpGs with intratumoral methyl-
ation heterogeneity was signiﬁcantly higher than the num-
ber of SNPs that were distinct among the regions
(Figure 3D) (2-sided t-test; P ¼ .0014), suggesting a relevant
and independent contribution of the epigenetic landscape to
intratumoral heterogeneity. Although for all intratumoral
sections, the tumoral component was 80% of the content
of the analyzed section, we wondered whether the observed
epigenetic heterogeneity could come from a different
cellular composition. Supplementary Table 3 shows the
percentage of the tumoral, stromal, and inﬂammatory
components for each 1 of the 3 studied intratumoralsections. The assignment of the most epigenetically diver-
gent intratumoral region did not correlate with the most
different section, according to the percentage of cellular
components (c2 test: P ¼ .56).
Liver Metastasis and its Epigenetic Resemblance
to Intratumoral Sections
We investigated which intratumoral region was most
similar to 23 liver metastases from the studied cases. Using
unsupervised analysis for each intratumoral section within a
given case and including its correspondingmetastasis sample,
we observed that themost frequent region of the primary CRC
that shared more methylation events with the metastasis was
the digestive TS (43.5%), followed by the IF (30.4%) and CB
(26.1%) (Supplementary Figure 7). Similar results were ob-
tained when we analyzed metachronous (n ¼ 13) and syn-
chronous (n ¼ 10) metastases separately (Supplementary
Figure 7). These results are interesting because the TS con-
stitutes the “oldest” part of the primary tumor,21 suggesting
that dissemination, in addition to the most advanced stages,
might also occur early in the carcinogenesis process. In this
regard, the fact that the available metastasis samples can be
closely related to the digestive tract region,which is thought to
represent ancestral lineages, supports the existence of a pro-
posed parallel progression model.22
Higher Epigenetic Homogeneity and Poor
Outcomes in Locoregional Disease
Finally, we studied whether the level of epigenetic het-
erogeneity in CRC had any impact in the outcomes in these
patients. The effects of heterogeneity in tumor progression
have been addressed using nucleotide23 and copy number
data,24 but it remains largely unexplored at the DNA
methylation level. For the 71 samples for which we had
complete clinical information (relapse and survival status,
Table 1), we observed from a qualitative manner that
knowing which intratumoral region was the more epige-
netically divergent did not exhibit prognostic value
(Supplementary Figure 8A). Then, we reanalyzed this issue
from a quantitative manner by determining the degree of
heterogeneity within each tumor, obtaining a coefﬁcient of
homogeneity based on the computation of the SD across the
3 regions in each patient for each CpG methylation site
located in a gene promoter region. Thus, the highest coef-
ﬁcient of homogeneity indicated the lower heterogeneity.
We did not observe any correlation between the obtained
coefﬁcient of epigenetic homogeneity and the differences in
the cellular components (tumoral, stromal, and inﬂamma-
tory) in each intratumoral region (c2 test: P ¼ .74). In this
regard, 47% (7 of 15) of the low epigenetic homogeneity
cases presented the same percentage of cellular composition
in each one of their intratumoral regions, whereas these last
cases constituted 52% (13 of 25) of the tumors in the high
epigenetic homogeneity group.
For the whole population with clinical data (n ¼ 71), a
nonsigniﬁcant trend between epigenetic homogeneity and
reduced relapse-free survival and overall survival was
observed (log-rank P ¼ .11 and P ¼ .08, respectively)
Figure 4. Impact of epigenetic heterogeneity in CRC outcome. (A) Kaplan-Meier analysis for relapse-free survival and overall
survival according to tumor EH level. High and low EH groups were established using the coefﬁcient SD mean promoters,
considering the median as threshold value between both groups of homogeneity. The P value corresponds to the log-rank
2-sided test. Number of events (relapse-free survival [RFS]: relapse; overall survival: death) are shown from 2 to 10 years in
high and low epigenetic homogeneity groups. (B) Forest plot representation of Cox proportional hazards regression analysis,
taking into account different clinical and histopathologic covariables in CRC cohort of patients with locoregional disease. The
P values correspond to HR. Concerning overall survival, Cox Regression is not assessed since there were no events (death) in
the low epigenetic homogeneity group.
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regression multivariate analysis (P ¼ .12 and P ¼ .09,
respectively) (Supplementary Figure 8C). In this cohort,
among all clinical variables collected for each patient,
advanced stage was the only independent prognostic factor
(HR, 2.41; 95% CI, 1.015.81; P ¼ .048) (Supplementary
Figure 8C). Therefore, in order to evaluate the effect ofepigenetic homogeneity in a more homogeneous CRC pop-
ulation, we stratiﬁed the cohort according to this parameter,
leaving 58 patients. We also excluded MSIþ cases (n ¼ 8)
due to the recognized association of this parameter with good
prognosis.25,26 Thus, we were able to determine the inﬂuence
of tumor epigenetic homogeneity in prognosis in a set of
50 patients with locoregional disease (stages I, II, and III)
Figure 5. Summary of our ﬁndings in CRC epigenetics highlighting than intertumoral epigenetic heterogeneity is higher than
intratumoral diversity; the identiﬁcation of the invasive front as the most epigenetically divergent region; the epigenetic
resemblance of liver metastasis to intratumoral sections; and the impact of epigenetic homogeneity on poor clinical outcomes.
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AT(Supplementary Table 4). We found that CRC patients
with locoregional disease and a higher epigenetic homoge-
neity coefﬁcient showed lower relapse-free survival (log-rank
P ¼ .037) and reduced overall survival (log-rank P ¼ .026)
(Figure 4A). According to Cox proportional hazard regression
models, higher epigenetic homogeneity was found to be an
independent prognostic factor for worse relapse-free survival
(HR, 2.91; 95% CI, 1.038.16; P ¼ .043) (Figure 4B). Our
results were further validated by performing a bootstrap
resampling procedure. Among 1000 new models, higher
epigenetic homogeneity remained an independent prognostic
factor for worse relapse-free survival (HR, 3.05; 95% CI,
1.048.90; P ¼ .042).
We also wondered whether the presence of selective
external pressures, such as cytotoxic drugs, could reverse
the value of higher epigenetic homogeneity to predict poor
outcomes. To address this issue, we included a new set of
stage IV CRC tumors for which patients received FOLFIRI
(folinic acid þ 5-ﬂuorouracil þ irinotecan) as ﬁrst-line
treatment (n ¼ 17) (Supplementary Table 5) after thedetermination of the degree of epigenetic heterogeneity in
the surgery specimens with the 3 described intratumoral
sections. Coefﬁcient of homogeneity “SDmean promoter”
was calculated and patients were divided in low and high
epigenetic homogeneity groups, using median as threshold
point, as we did. The association between level of homo-
geneity and clinical covariables was determined using c2
tests or Fisher’s exact test whenever required; P < .05 was
considered as statistically signiﬁcant (Supplementary
Table 5). Interestingly, and in concordance with our previ-
ous results in the CRC cohort with locoregional disease, high
epigenetic homogeneity was associated with worse
response rate to treatment (85.7% of nonresponder cases
belonged to high epigenetic homogeneity group; Fisher’s
exact test; P ¼ .049) and poor survival in these new sets of
patients treated with FOLFIRI (75% of exitus cases
belonged to high epigenetic homogeneity group, whereas for
the low epigenetic homogeneity group, a 100% of the pa-
tients remained alive; Fisher’s exact test; P ¼ .009)
(Supplementary Table 5). Overall, these results could
November 2016 Predicting Outcomes in Patients With CRC 971pinpoint that those tumors with a lower heterogeneity are
driven by powerful clonal events that are associated with
expansive growth and more aggressive clinical behavior.BA
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Intertumoral differences in CRC at the genetic3 and
epigenetic4 levels occur and have made it possible to
establish a consensed molecular classiﬁcation of potential
subtypes of CRC.26 However, the existence of intratumoral
molecular diversity within each CRC patient and its poten-
tial impact on outcomes, generation of metastasis, and
development of chemoresistance, have been explored to a
lesser degree. In this regard, genomic sequencing studies
that addressed the presence of distinct mutational proﬁles
between different intratumoral regions of primary and
metastases indicate that molecular heterogeneity is a com-
mon ﬁnding.27,28 Even distinct metastases from the same
patient can show a certain degree of genetic diversity.27,28
These different molecular setting can have a relevant role
in outcomes and response to targeted therapies.29 For
example, the therapeutic use of epidermal growth factor
receptor blockade in CRC patients could induce the
outgrowth of intratumoral regions carrying KRAS mutations
or carrying other molecular events associated with activa-
tion of mitogen-associated protein kinases.30,31
The contribution of epigenetic changes, such as DNA
methylation aberrations, to intratumoral heterogeneity have
been less studied despite the well-recognized contribution
to carcinogenesis of these chemical modiﬁcations of the
genome. For CRC, relevant tumor suppressor genes are
inactivated by promoter CpG island hypermethylation32 and
some genomic sites acquire hypermethylation frequently,
mostly in the MSIþ context, conﬁguring the CpG island
hypermethylation phenotype.16 However, despite that re-
ports reﬂect the existence of intratumoral epigenetic het-
erogeneity for other malignancies such as prostate33 and
breast34 cancers, we know extremely little about this phe-
nomenon in CRC. In this study, the determination of the
DNA methylation landscape of 288 intratumoral sections
corresponding to 96 CRC patients contributes to ﬁll the
knowledge gap in the ﬁeld. Our ﬁndings are summarized in
Figure 5. Our results demonstrates that intertumoral DNA
methylation proﬁles are always more distinct than intra-
tumoral proﬁles. However, we also show that in CRC pri-
mary tumors, intratumoral DNA methylation differences
occur and, most of the time, are more extensive than the
analyzed genetic diversity. Among the 3 studied intra-
tumoral sections, the invasive front was the most signiﬁ-
cantly epigenetically divergent. These data agree with the
proposed role of the invasive front as a critical region in CRC
that undergoes expression changes in adhesion and EMT
proteins,20 some of them in a transient manner.35 This ﬁts
with the dynamic nature of the epigenetic changes. Our
results also show that the corresponding metastasis can
resemble any intratumoral region, but were most often
similar to the region closest to the gastrointestinal transit,
the oldest part of the tumor. This provides a potential
explanation for the early occurrence of metastasis, even forthose more localized and small carcinomas. Finally, we also
found that those locoregional CRC tumors more homoge-
neous at the epigenetic level show poor clinical outcomes.
The same effect is observed in more advanced cases that
received the standard chemotherapy FOLFIRI treatment as
ﬁrst-line therapy. Prospective studies are now necessary to
demonstrate whether the use of the newly developed tar-
geted therapies will have an impact on shifting the
described epigenetically divergent regions toward ones that
harbor an enriched population of resistant cells.Supplementary Material
Note: To access the supplementary material accompanying
this article, visit the online version of Gastroenterology at
www.gastrojournal.org, and at http://dx.doi.org/10.1053/
j.gastro.2016.08.001.References
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